Blog: Affordable Care Act
April 1, 2015 | Affordable Care Act, USA
What does the future hold for the US pharma industry?
Everywhere you go in the States, you hear talk of the Affordable Care Act, also known as ObamaCare. In essence, the ACA is designed to broaden coverage to the millions of Americans who have not had healthcare in the past due to not being employed or just not being able to afford it. ACA had a rocky time getting passed into law and now that it has launched on January 1, 2014, things are not getting much easier. After the President promised that no one who likes his/her doctor would have to switch doctors, some folks are being dropped by their insurance and do have to leave their doctors. Younger people almost certainly have to pay more than they have been paying for coverage because the way the new system is structured, younger, healthier people are underwriting the costs for older people who utilize the healthcare system more frequently (and at greater cost). At the core of the debate is a values questions: some people truly believe that everyone should have access to the healthcare system as provided by the ACA. Others exude a really American spirit of not wanting any government intervention or interference in their lives. So despite the fact that this program might be advantageous to many, it represents an intrusion. This disagreement is unlikely to be easily resolved as it is a core values question.
It has been almost a given that full time employees offer some level of healthcare coverage to employees and some employers are taking advantage of this shift in the landscape to divorce employment from healthcare benefits and force their employees to shop independently for coverage on the newly created exchanges. In fact, this has happened to my own husband. So this represents added expense to the employees, unless the employers decide to underwrite the cost in some way (which has yet to be determined). This is “a great unknown” and something that will be determined company to company, not on a national level.
There are some facts that are emerging, although the system is still unfolding. Some folks will have to change physicians and physicians will have to see more patients, possibly at a lower reimbursement rate than before. The rates themselves are still unclear and may not be clear for quite some time. The system is structured so that everyone will have access to care; in fact, everyone must have access to care. That means that there are financial penalties if people don’t sign up.
So everyone is a bit at sea. Pharma companies, too are wondering about the impact of the ACA on their worlds. What guidelines will physicians have to follow in prescribing? What tests will be covered? What types of reporting will they have do (electronic record keeping)? I spoke to my colleague from our sister company, Access Partnership about this. His idea is that things are unclear in part because, although the Supreme Court upheld the centerpiece of the Affordable Care Act more than a year ago, there are still several legal challenges to the new system, which may slow down the implementation and make it difficult to envision how the new system will play out over time.
As of right now, the Affordable Care Act is just beginning and it is difficult to see “around the next bend” as to what the long term implications will be for the interested parties (and by that I mean everyone!).
Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more here: http://bit.ly/1Pj6vu1
This content was provided by Inizio
Company Details
Latest Content from Inizio
Research Partnership and Janssen are 2017-18 BOBI Awards finalists
We are delighted to announce that an entry submitted by Research Partnership with Janssen has been selected as a finalist in the Best Business Impact category at this year’s BOBI...
Portfolio analysis: Making Go/No-Go decisions to optimise the portfolio
Tuesday 20th March 2018 11:00 EST / 16:00 GMT / 17:00 CEST
PMRC New Jersey round up 2018
Earlier this month, Directors Tom Nolte and Melinda Shorr attended the Pharmaceutical Market Research Conference in Newark, New Jersey
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis
You can probably remember at least one of your friends in school who was always scratching and suffered from red, scaly skin rashes, perhaps on their elbows or backs of...
Good intentions, bad habits: Reforming mental healthcare in Latin America and the Caribbean
In the second of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Latin America and the Caribbean
How we applied user-led design thinking in the ER setting to improve patient care
The challengeOur client needed to identify the key delivery-device attributes for an antibiotic topical treatment used to combat a group of infections typically affecting young children. Current treatment is a...
Research conducted by Research Partnership published in leading medical journal
Findings from a study conducted by Research Partnership have recently been published in the ‘Supportive Care in Cancer’ journal
Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
Hiding between the lines of any company’s ledgers is an intangible asset, invisible to most auditors, but with the potential to have a very real impact on bottom line. Pharma...
Webcast: Rich in potential – Exploring the opportunity for nutritionals in emerging markets
Watch the webcast: http://bit.ly/2oTpzFjA shift to preventative health has seen nutritionals emerge as a rapidly developing area in recent years. But while growth begins to level off in more established territories,...
A researcher’s guide to Key Driver Analysis
Research Manager Kayleigh Simpson explores how Key Driver Analysis can be used to answer key business